Pyxis Oncology, Inc. (PYXS): Shareholders' Equity
$53.41M
As of 2025-12-31
$11.44M
As of 2026-06-30
-30.8%
3-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $53.41M | -55.8% | 2026-03-23, Balance as of period end |
| 2024-12-31 | $120.75M | -3.9% | 2026-03-23, Balance as of period end |
| 2023-12-31 | $125.70M | -21.8% | 2025-03-18, Balance as of period end |
| 2022-12-31 | $160.82M | -38.5% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $261.31M | n/m | 2023-03-22, Balance as of period end |
| 2020-12-31 | -$15.64M | n/a | 2022-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | 2025-12-31 | $53.41M | -55.8% |
| CV Sciences, Inc. (CVSI) | 2025-12-31 | $1.47M | -18.2% |
| Arbutus Biopharma Corp (ABUS) | 2025-12-31 | $76.58M | -21.4% |
| Opus Genetics, Inc. (IRD) | 2025-12-31 | $15.35M | +128.3% |
| Palatin Technologies Inc (PTN) | 2026-06-30 | $6.69M | n/m |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | 2025-12-31 | $245.15M | +75.7% |
| Evommune, Inc. (EVMN) | 2025-12-31 | $205.57M | n/m |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | -$63.61M | n/m |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $68.64M | -47.8% |
Compare PYXS, CVSI, ABUS, IRD side by side · Screen every company in Pharmaceutical Preparations ↗